top of page
One Year of Qubigen: From Federated AI Vision to Scalable Drug Design Reality
As Qubigen approaches the end of 2025, we mark an important milestone: our first year of operation. In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value across the life sciences ecosystem. This first year has been defined by three converging forces: strong technical performance, globa
Dec 23, 20254 min read
Qubigen to Attend JPM Week 2026 in San Francisco, Engaging Investors & Exploring Strategic Partnerships
Qubigen is pleased to announce its participation at JPM Week 2026 in San Francisco, the premier global gathering for biotech, pharma, medtech, and life sciences investment. JPM Week sees hundreds of industry leaders, investors, innovators and entrepreneurs convene each January in San Francisco, offering a unique moment to build partnerships, explore business development and invest in the future of healthcare innovation. Qubigen Attendees Representing Qubigen at JPM Week wil
Dec 2, 20252 min read
QIMR Berghofer Engages with Qubigen to Advance AI-Driven Research in Cancer Pathways
Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer , one of Australia’s leading medical research institutes. The agreement establishes a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression. By combining Qubigen’s computational modelling and quantum chemistry capabilities with QIMR Berghofer’s deep expertise in translational cancer biology, this partnership aims to illuminate new therapeuti
Nov 19, 20252 min read
bottom of page